Yabao Pharmaceutical announced that its wholly-owned subsidiary Yabao Pharmaceutical Sichuan Pharmaceutical Co., Ltd. received two “Drug Registration Certificates” for levocetirizine hydrochloride oral solution approved and issued by the State Drug Administration. This medicine is suitable for a variety of allergy symptoms and can be used for people over 6 months. Domestic sales in 2025 amounted to 461 million yuan. As of the announcement date, in addition to the company, 27 domestic enterprises have received registration approval. The company has invested 5.06 million yuan in R&D expenses. Production and sales will be promoted in the future, but there is uncertainty.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.